Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Gene Therapy
Zemi Dossier
Research-use only
In Vivo Gene Editing
A decision package on the coupling tax between editing efficiency, delivery, immune sensing, durability, safety, and manufacturing reality.
Decision this dossier helps answer
Which in-vivo editing programs are limited by edit chemistry, delivery, immune response, durability, or CMC before pivotal spend?
Problem this dossier solves
The weakest coupled gate controls the program.
The dossier argues that in-vivo editing cannot be evaluated one axis at a time. A strong editor fails if delivery, immune response, durability, safety margin, or manufacturability breaks the integrated system.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
101-page research report plus 38-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The weakest coupled gate controls the program.
The dossier argues that in-vivo editing cannot be evaluated one axis at a time. A strong editor fails if delivery, immune response, durability, safety margin, or manufacturability breaks the integrated system.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual In Vivo Gene Editing research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Report Scope & Evidence Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Brief: Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| 2026 Translational Signal Update (+ Evidence Refresh Addendum) | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Lets the buyer audit support strength before relying on the package. |
| Current-Signal Refresh (Fresh-Scan Frontier, as of 13 June 2026) | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Currency Corrections and Model Defense | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Snapshot | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Dashboard | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| How Each Buyer Should Use This Dossier | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The Integrated-System Model | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Coupling Tax and the DCC Classifier | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The law: Conservation of Coupled Risk | Defines the governing argument and the evidence gates that would support or falsify it. | Shows where the thesis could fail or require more validation before action. |
| Liver is the most forgiving corner, not a free one | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The instrument: the Dominant Coupled-Constraint (DCC) classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Mechanistic Deep Dive: The Six Binding Constraints | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Constraint 1 - DELIVERY: the cytosolic-arrival bottleneck | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Constraint 2 - INNATE-SENSING: the immunogenicity floor | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Constraint 3 - ADAPTIVE-IMMUNITY: the re-dosing and access gate | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Constraint 4 - COMPLEMENT-TMA: the safety-critical systemic-dose ceiling | Defines the governing argument and the evidence gates that would support or falsify it. | Shows where the thesis could fail or require more validation before action. |
| Constraint 5 - DURABILITY-INTRINSIC: the transgene-and-tissue biology that the vector cannot fix | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Constraint 6 - GENOTOXICITY: the safety-critical specificity ceiling | Defines the governing argument and the evidence gates that would support or falsify it. | Shows where the thesis could fail or require more validation before action. |
| The Re-Dosing Problem in Depth | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Platform Comparison & Evidence Maturity Matrix | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Platform Deep-Dive Profiles | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Platform Diligence: Extended Notes | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Failure-Mode Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross-Domain Synthesis | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Non-Obvious Early Opportunities | Connects research maturity to competitive position, program strategy, and diligence watchpoints. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Key Findings & Quantitative Evidence | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Lets the buyer audit support strength before relying on the package. |
| Mechanistic Insights | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Safety, Immunogenicity & Genotoxicity Risks | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Safety, Risk and Failure Modes: A Systematic Account | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Shows where the thesis could fail or require more validation before action. |
| Durability Benchmarks & Tissue Gradient | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Translational Readiness: The Platform Ladder | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1. Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Sheet, Purpose fields and clipped entries such as 2. Claim Ledger, 62 customer-facing claims, full., 3. Evidence Table. |
| 2 | 3. Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes identifier, title, journal, year fields and clipped entries such as PMID:40457105, Dual SORT lipid nanoparticles for., Nature biotechnology. |
| 3 | 6. Platform Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Platform, Representative, Delivery efficiency, Innate signature fields and clipped entries such as Liver AAV (secreted protein), AAV5/8/9 +. |
| 4 | 7. Triad Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Axis, Solved status, Dominant bottleneck, Strongest evidence fields and clipped entries such as Durability, NOT individually solved, Anti-capsid. |
| 5 | 11. Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes id, study, why it matters, model fields and clipped entries such as NS1, Single-cohort multi-parameter study., No study measures all three. |
| 6 | 12. Validation Gates | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes gate, statement, PASS criteria, FAIL criteria fields and clipped entries such as VG1, Tolerogenic delivery achieves., Efficacy + reduced immune. |
| 7 | 13. OffTarget-Immuno Assays | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes assay, class, sensitivity/scope, LoD/notes fields and clipped entries such as In-silico prediction, Off-target, Low / context-blind. |
| 8 | 14. CMC Risk Matrix | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes risk, severity, likelihood, impact fields and clipped entries such as Empty-capsid / aggregate load, High, High. |
| 9 | 15. Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes item, status, relevance, provenance fields and clipped entries such as FDA Apr 2026 draft: Safety., Draft guidance (Apr 2026),.,. |
| 10 | 16. Company-Funding Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes sponsor, product, indication, status fields and clipped entries such as Intellia Therapeutics, lonvo-z (lonvoguran ziclumeran,., Hereditary. |
| 11 | 17. Trial-Registry Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes nct, official_title, sponsor, phase fields and clipped entries such as NCT06128629, MAGNITUDE: A Phase 3, Multinational,., Intellia Therapeutics. |
| 12 | 18. 2026 Update Sources | Monitoring surface for emerging signals, update triggers, and evidence changes that could alter the decision. Public preview exposes 40499172, Hemophilia durability, UPDATE, Sustained Clinical Benefit of AAV. fields and clipped entries such as Safety /. |
| 13 | 19. Expert Review | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Scope, All customer-facing claims. fields and clipped entries such as Method, Live verification via NCBI eutils,., Key correction. |
| 14 | 20. Gate Compliance Ledger | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes gate, requirement, status, proof fields and clipped entries such as G0, Read actual sources, never., PASS. |
| 15 | 21. Excluded Claims | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes label, claim_text (truncated), disposition, citation fields and clipped entries such as Excluded 1 — Espacenet patent.,. |
| 16 | 24. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1 (H-DCC), S-F1, DCC-matched de-risking vs. |
| 17 | 24b. Power Sensitivity | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes #, hypothesis_id, test_type, n @1.0x eff, pw .80 fields and clipped entries such as F1 (H-DCC), Two-proportion, F2 (H1). |
| 18 | DCC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness, fraction of the 6 axes with., ____ fields from this sheet. |
| 19 | DCC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Axis (constraint class), Meaning (rubric: 3 = severe., Deficit 0-3 (ENTER), Weight (expert-init) fields and clipped entries such as. |
| 20 | DCC_Vector_Rules | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Delivery vector class, Matched delivery architecture, Contraindication, Safety flag fields and clipped entries such as. |
| 21 | DCC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness (ENTER 0-1), 0.8 fields and clipped entries such as Delivery vector class (ENTER., LNP, Archetype (deficit scores). |
| 22 | DCC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Class (binding constraint), Recommended strategy, Primary functional endpoint, Required safety readout fields and clipped entries such as. |
| 23 | DCC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Assay / readout, Axis, Tier fields and clipped entries such as % target-cell editing at target dose., Delivery, Required. |
| 24 | DCC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile (deficits D,I,A,C,Dur,G), Binding constraint, Matched move fields and clipped entries such as Liver LNP base-edit (e.g.. |
| 25 | DCC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Linked flagship, F1 (DCC-matched de-risking beats. fields and clipped entries such as Validation cohort, programs/candidates profiled on all.,. |
| 26 | DCC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes DCC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Delivery axis, endosomal-escape tax;., PMID. |
| 27 | 2. Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, claim_text, section, page_anchor fields and clipped entries such as C01, Finding 1 — Dual Selective., Clinical & Translational. |
| 28 | 10. Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes hypothesis_id, tier, power_calc_row, statement fields and clipped entries such as F1, Flagship, S-F1 (F1; +F5 AUC>=0.80). |
| 29 | 22. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes #, Report section / page, Claim text, Evidence layer fields and clipped entries such as Clinical & Translational., Finding 1 — Dual. |
| 30 | 4. Source Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes Finding / claim, Source ID, Support verdict (6-way), Verbatim excerpt from source fields and clipped entries such as Finding 1 — Dual Selective.,. |
| 31 | 5. Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Total claims audited (full pack), 130 fields and clipped entries such as Customer-facing (kept), Excluded - off-topic (below.. |
| 32 | 23. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Figure / scale, Scale, What each level means, Basis / anchor fields and clipped entries such as FIG-03 Evidence Maturity Heat Map, 0-4 per cell,. |
| 33 | 25. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality, Target / indication fields and clipped entries such as Intellia Therapeutics, lonvo-z (NTLA-2002), in vivo. |
| 34 | 26. DCC Classifier (Guide) | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Sheets, DCC_Input_Template -. fields and clipped entries such as What it does, Given a program's 6-axis deficit., Output classes. |
| 35 | 27. Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v1.0 (base), June 2026, Audit-passed., prior build fields and clipped entries such as Controlling model, Coupling Tax v1.0,. |
| 36 | 28. Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes ID, Issue, Status, Resolution / note fields and clipped entries such as AI-1, Power calculations executable for., RESOLVED. |
| 37 | 8. Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes report_figure, figure_id, title, family fields and clipped entries such as Figure 1, FIG-18, Catalyst / trial / funding timeline. |
| 38 | 9. Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes report_figure, figure_id, file, engine fields and clipped entries such as Figure 1, FIG-18, fig18_*.png. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 (H-DCC) | DCC-matched de-risking vs off-axis: durable functional-editing success | Two-proportion | 0.65 | 0.05 | 0.80 | 62 | 62 |
| F2 (H1) | Innate-sensing index dominates durability (H1): high vs low sensing | Two-proportion | 0.55 | 0.05 | 0.80 | 61 | 61 |
| F3 (H5) | Transgene-specific durability (H5): FVIII-vs-FIX decline slope | Two-sample t | 0.7 | 0.05 | 0.80 | 33 | 33 |
| F4 (H2/H6) | Delivery-efficiency x immunogenicity Pareto break (H2): joint success | Two-proportion | 0.72 | 0.05 | 0.80 | 76 | 76 |
| F5 (H-DCC) | DCC classifier reserve index: dominant-axis prediction AUC | AUC (Hanley-McNeil, external) | 0.8 | 0.05 | 0.80 | 260 | 260 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 101-page report + 38-sheet workbook
Buy now
- Decision research report (101 pages, PDF)
- Evidence & Decision Workbook (38 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price